• Zhaozhou Zhang, Liqing Du, Qiuchen Ji, Hao Liu, Zhenxing Ren, Guang Ji, Zhao-Xiang Bian, and Ling Zhao.
• School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China.
• Am. J. Chin. Med. 2024 Jan 1; 52 (1): 8912289-122.

AbstractLiver Stagnation and Spleen Deficiency (LSSD) is a Chinese Medicine (CM) pattern commonly observed in gastrointestinal (GI) diseases, yet its biological nature remains unknown. This limits the global use of CM medications for treating GI diseases. Recent studies emphasize the role of gut microbiota and their metabolites in the pathogenesis and treatment of LSSD-associated GI diseases. There is increasing evidence supporting that an altered gut microbiome in LSSD patients or animals contributes to GI and extra-intestinal symptoms and affects the effectiveness of CM therapies. The gut microbiota is considered to be an essential component of the biological basis of LSSD. This study aims to provide an overview of existing research findings and gaps for the pathophysiological study of LSSD from the gut microbiota perspective in order to understand the relationship between the CM pattern and disease progression and to optimize CM-based diagnosis, prevention, and therapy.

10 keywords...

hide…